ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma PatientsBusiness Wire • 05/04/21
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV ReservoirsBusiness Wire • 04/29/21
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple IndicationsBusiness Wire • 04/22/21
ImmunityBio: Remaining Bullish As Global Vaccine Apparatus Continues To MisfireSeeking Alpha • 04/16/21
Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell ResponsesBenzinga • 04/08/21
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2Business Wire • 04/08/21
ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of DirectorsBusiness Wire • 04/01/21
ImmunityBio's Prostate Cancer Vaccine Shows Early Signs Of Clinical Activity, Durable Stable DiseaseBenzinga • 03/29/21
ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate CancerBusiness Wire • 03/29/21
ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant TumorsBusiness Wire • 03/22/21
